Tuesday, 19 October 2021

Windlas Biotech, Mateon Therapeutics launch complete respiratory wellness solution

08 March 2021 | News

The platform is a self-assessment and monitoring tool that provides >90 per cent accurate feedback

Source credit: Shutterstock

Source credit: Shutterstock

Gurugram based Windlas Biotech, in partnership with Mateon Therapeutics in the US, has launched an innovative drug-device therapy PulmoHeal + ARTIHealth as a complete respiratory wellness solution.

In a first, the AI-app based platform ARTIHealth™, developed by Mateon Therapeutics will enable patients to monitor the progress of their respiratory function over time by enabling them to upload daily cough and speech recording and receiving feedback on the health of their lungs.

The platform is a self-assessment and monitoring tool that provides >90 per cent accurate feedback used for suitable self-care and remote healthcare. This is part of a long-term joint development agreement with IBM Watson Health Research and Mateon. 

The platform will also collect large-scale, clinical data through a post-marketing survey (PMS) platform through which we are empowering consumers and patients as active participants in the development of PulmoHeal for future indications including COVID-19, COPD, and asthma.

Interim results from the clinical study called ARTI-19 conducted by Windlas and Mateon suggest PulmoHeal to be highly effective in significantly reducing respiratory distress and has demonstrated efficacy against COVID-19 as well. These results have been published in prestigious peer-reviewed journals Frontiers in Pharmacology and Clinical Investigations.

The trials were carried out on 120 patients across three hospitals in Andhra Pradesh and Maharashtra.

Hitesh Windlass, MD, Windlas Biotech, commented, “PulmoHeal might have the potential to fight a broad spectrum of respiratory viruses. Our new drug-device platform will be a game-changer and will significantly reduce the burden on health systems.”

Dr Vuong Trieu, CEO and Chairman, Mateon said, “Artemisinin is a highly promising TGF-β inhibitor and opens the way to alleviating many respiratory illnesses.”

The research is supported by Chopra Foundation, a non-profit organisation, dedicated to improving health and well-being. Interim findings on the clinical trial of Ayurvedic variant of PulmoHeal, ARTIVeda have been submitted to AYUSH authorities for medical evaluation.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account